Bolt Biotherapeutics, Inc. (BOLT): Price and Financial Metrics
BOLT Price/Volume Stats
| Current price | $1.68 | 52-week high | $2.72 |
| Prev. close | $1.70 | 52-week low | $1.18 |
| Day low | $1.65 | Volume | 79,691 |
| Day high | $1.81 | Avg. volume | 229,425 |
| 50-day MA | $1.60 | Dividend yield | N/A |
| 200-day MA | $1.52 | Market Cap | 63.53M |
BOLT Stock Price Chart Interactive Chart >
BOLT POWR Grades
- BOLT scores best on the Sentiment dimension, with a Sentiment rank ahead of 87.23% of US stocks.
- The strongest trend for BOLT is in Stability, which has been heading down over the past 179 days.
- BOLT's current lowest rank is in the Stability metric (where it is better than 17.46% of US stocks).
BOLT Stock Summary
- BOLT BIOTHERAPEUTICS INC's stock had its IPO on February 5, 2021, making it an older stock than merely 9.36% of US equities in our set.
- With a price/sales ratio of 10.49, BOLT BIOTHERAPEUTICS INC has a higher such ratio than 90.04% of stocks in our set.
- Revenue growth over the past 12 months for BOLT BIOTHERAPEUTICS INC comes in at 225.23%, a number that bests 96.73% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to BOLT BIOTHERAPEUTICS INC are IKNA, SELB, IPSC, ATHX, and SIMO.
- Visit BOLT's SEC page to see the company's official filings. To visit the company's web site, go to www.boltbio.com.
BOLT Valuation Summary
- BOLT's price/earnings ratio is -0.9; this is 103.73% lower than that of the median Healthcare stock.
- Over the past 28 months, BOLT's EV/EBIT ratio has gone up 16.6.
Below are key valuation metrics over time for BOLT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BOLT | 2023-05-23 | 10.9 | 0.5 | -0.9 | -1.0 |
| BOLT | 2023-05-22 | 10.7 | 0.5 | -0.9 | -1.0 |
| BOLT | 2023-05-19 | 10.8 | 0.5 | -0.9 | -1.0 |
| BOLT | 2023-05-18 | 10.6 | 0.5 | -0.9 | -1.0 |
| BOLT | 2023-05-17 | 10.1 | 0.4 | -0.8 | -0.9 |
| BOLT | 2023-05-16 | 10.4 | 0.4 | -0.9 | -0.9 |
BOLT Price Target
For more insight on analysts targets of BOLT, see our BOLT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $39.75 | Average Broker Recommendation | 1.2 (Strong Buy) |
Bolt Biotherapeutics, Inc. (BOLT) Company Bio
Bolt Biotherapeutics, Inc. operates as a biotechnology company. The Company develops immune-stimulating antibody conjugates, a new class of cancer therapeutics, which systemically-administered and uncover the immune system to induce anti-tumor immunity. Bolt Biotherapeutics serves healthcare industry in the United States.
Latest BOLT News From Around the Web
Below are the latest news stories about BOLT BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate BOLT as an investment opportunity.
BioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseasesBioLight (TASE: BOLT) is proud to report it has signed a research collaboration agreement with Alexion (AstraZeneca Rare Disease), focusing on exploring a groundbreaking technology that utilizes natural tears for the potential diagnosis of retinal diseases. |
Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual MeetingTreatment with BDC-1001 at the recommended Phase 2 dose (RP2D) resulted in 29% objective response rate in evaluable patients with HER2-positive tumors, in both monotherapy and in combination with nivolumab20 mg/kg dosed every other week (q2w) was selected as the RP2DBDC-1001 advancing to a focused Phase 2 clinical program in four HER2-positive tumor types: colorectal, endometrial, gastroesophageal, and breast REDWOOD CITY, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasd |
Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateComprehensive BDC-1001 clinical safety and efficacy data as a single agent and in combination with nivolumab, including RP2D, to be presented at ASCO 2023BDC-1001 Phase 2 program expected to initiate in 2023 in HER2+ colorectal, endometrial, gastroesophageal, and breast cancerCash balance of $171.0 million anticipated to fund key clinical milestones through 2025 REDWOOD CITY, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical co |
Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual MeetingComprehensive Phase 1 data at ASCO support initiation of two Phase 2 trialsREDWOOD CITY, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the treatment of cancer, today announced that it will present a poster with clinical data from its completed Phase 1 dose-escalation study of BDC-1001 at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting. The con |
Investors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 47% over the last yearIt's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly... |
BOLT Price Returns
| 1-mo | 4.35% |
| 3-mo | 3.70% |
| 6-mo | 20.86% |
| 1-year | -18.05% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 29.23% |
| 2022 | -73.47% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...